A Houston space medicine research organization has partnered with a video game maker that has created surgery simulation technology. Photo via levelex.com

A Houston-based organization affiliated with NASA has teamed up with a video game company to advance virtual simulation in space medicine.

The Translational Research Institute for Space Health, known as TRISH, in partnership with NASA in a consortium led by Baylor College of Medicine, California Institute of Technology in Pasadena, and Massachusetts Institute of Technology in Cambridge has advanced a new approach for space medicine using video game technology by collaborating with video game company, Level Ex.

"We discovered Level Ex through a process of landscaping the many virtual simulation companies that were out there," says Andrew Peterman Director of Information System at TRISH. "We especially noted those that were on the cutting edge of the technology."

Based in Houston, TRISH aims to collaborate with the best and the brightest to revolutionize space health, providing grants to companies with innovative concepts. With Level Ex, they found a new approach to decode earthly medical technologies in space.

Level Ex, a Chicago-based company created in 2015 was founded to provide training games for doctors to use to practice surgeries and procedures. The games are interactive, with the virtual patient reacting to the actions of the player. The training simulations consist of in-depth and physics-driven medical simulations that are verified by doctors in their advisory board.

"We're hoping to completely change the ways that doctors stay up to speed," says Level Ex founder-and-CEO Sam Glassnberg.

With their ongoing collaboration with TRISH, they have a challenge that's out of this world. In space, astronauts have limited space for medical tools and run on a limited crew. This makes providing basic medical training to all astronauts especially important.

Especially since the body begins to react to the new environmental conditions of space missions. The effects can be small or lead to new changes or challenges for astronauts who take on long-range missions. Astronauts may see their bodies slowly start to lose bone and muscle mass. Their fluid begins to shift toward their head, leading to increased risks of hypertension and thrombosis.

All of these are challenges NASA is working to address with the help of gaming technology from Level Ex that innovates the technology with higher-level capability and training. Combining video game technology and medical simulation applications to incorporate and explore the interplay of environmental conditions found in space.

"What we really liked about Level Ex is that they have an amazing team both on the clinical and technical side, says Peterman. "They are a group of former big-name game developers who along with clinical experts have married technology and medicine with their platform producing full in engine physics-driven real simulations rather than video playback."

The astronauts will train using simulations that allow them to practice a procedure in zero gravity conditions and even simulate the gravity conditions of Mars. The game will also allow astronauts to get their own on-screen avatar with their medical information thus allowing fellow astronauts to gain more practice and experience with fewer variables in space.

The advanced medical simulation platform has potential for commercial uses on earth, improving the range of the technology to simulate new, rare, and complex scenarios across a range of medical specialties, allowing doctors to practice a range of difficult scenarios without putting patient lives at risk.

Peterman says that the partnership is expected to continue into the future for immediate applications along with other innovations in astronaut healthcare, including autonomous frameworks to provide medical knowledge in outer space.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”